BC Week In Review | Nov 10, 2014
Clinical News

MBC-11: Phase I started

Osteros Biomedica began an open-label, dose-escalation Phase I trial to evaluate single and multiple doses of MBC-11 in 18 patients with bone lesions from cancer. Osteros has exclusive, worldwide rights to develop and commercialize MBC-11...
BC Week In Review | Nov 17, 2008
Clinical News

Aclasta regulatory update

FDA said that a review of data from nearly 40,000 patients in placebo-controlled trials of four marketed bisphosphonates showed no clear association between bisphosphonate exposure and the rate of atrial fibrillation (AF). The review followed...
BC Week In Review | Nov 3, 2008
Clinical News

Forteo teriparatide regulatory update

U.K.'s NICE issued final guidance on the use of drugs for both primary and secondary prevention of fractures in postmenopausal women with osteoporosis. The agency recommended the use of Fosamax alendronate from Merck for primary...
BC Extra | Oct 28, 2008
Company News

NICE issues osteoporosis guidance

The U.K.'s NICE issued final guidance on the use of drugs for both primary and secondary prevention of fractures in postmenopausal women with osteoporosis. NICE recommended the use of Fosamax alendronate from Merck (NYSE:MRK) for...
BC Week In Review | Jul 14, 2008
Clinical News

Actonel risedronate regulatory update

U.K.'s NICE issued a final appraisal determination recommending use of Actonel risedronate or Didronel etidronate as the first alternative treatment option for the prevention of osteoporosis in postmenopausal women who are unable to take alendronate....
BC Week In Review | Jul 14, 2008
Clinical News

Didronel etidronate regulatory update

U.K.'s NICE issued a final appraisal determination recommending use of Actonel risedronate or Didronel etidronate as the first alternative treatment option for the prevention of osteoporosis in postmenopausal women who are unable to take alendronate....
BC Week In Review | Jan 14, 2008
Clinical News

Didronel etidronate regulatory update

Based on an ongoing review of post-marketing reports, FDA issued a warning to inform healthcare professionals and patients that treatment with bisphosphonates may result in severe and possibly incapacitating musculoskeletal pain. FDA said the association...
BC Week In Review | Oct 9, 2006
Clinical News

Etidronate regulatory update

The U.K.'s NICE published draft guidance for compounds as primary prevention of osteoporosis-related fractures in postmenopausal women. The guidance recommends that etidronate be used as an alternative treatment option for primary prevention in women with...
BioCentury | Sep 6, 2004
Strategy

Back to School: Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
BioCentury | Jan 5, 2004
Strategy

Sequenom's target practice

Through its genome screening technology, Sequenom Inc. has generated targets in 11 disease areas. Like many target companies, SQNM now has determined that it has more targets than capacity. Thus, SQNM believes that its first...
Items per page:
1 - 10 of 14